Healthcare disparities, screening, and molecular testing in the changing landscape of non-small cell lung cancer in the United States: a review.
Biomarker testing
Healthcare disparities
Lung cancer screening
Non–small cell lung cancer
Journal
Cancer metastasis reviews
ISSN: 1573-7233
Titre abrégé: Cancer Metastasis Rev
Pays: Netherlands
ID NLM: 8605731
Informations de publication
Date de publication:
16 May 2024
16 May 2024
Historique:
received:
25
01
2024
accepted:
04
04
2024
medline:
16
5
2024
pubmed:
16
5
2024
entrez:
15
5
2024
Statut:
aheadofprint
Résumé
Inequitable access to care continues to hinder improvements in diagnosis and treatment of lung cancer. This review describes healthcare disparities in the changing landscape of non-small cell lung cancer (NSCLC) in the United States, focusing on racial, ethnic, sex-based, and socioeconomic trends. Furthermore, strategies to address disparities, overcome challenges, and improve patient outcomes are proposed. Barriers exist across lung cancer screening, diagnosis, and treatment regimens, varying by sex, age, race and ethnicity, geography, and socioeconomic status. Incidence and mortality rates of lung cancer are higher among Black men than White men, and incidences in young women are substantially greater than in young men. Disparities may be attributed to geographic differences in screening access, with correlating higher incidence and mortality rates in rural versus urban areas. Lower socioeconomic status is also linked to lower survival rates. Several strategies could help reduce disparities and improve outcomes. Current guidelines could improve screening eligibility by incorporating sex, race, and socioeconomic status variables. Patient and clinician education on screening guidelines and patient-level barriers to care are key, and biomarker testing is critical since ~ 70% of patients with NSCLC have an actionable biomarker. Timely diagnosis, staging, and comprehensive biomarker testing, including cell-free DNA liquid biopsy, may provide valuable treatment guidance for patients with NSCLC. Efforts to improve lung cancer screening and biomarker testing access, decrease bias, and improve education about screening and testing are needed to reduce healthcare disparities in NSCLC.
Identifiants
pubmed: 38750337
doi: 10.1007/s10555-024-10187-6
pii: 10.1007/s10555-024-10187-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 17–48. https://doi.org/10.3322/caac.21763
doi: 10.3322/caac.21763
pubmed: 36633525
American Cancer Society Inc. (2023). Cancer facts and figures. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer-facts-figures.html . Accessed 13 Jul 2023
Araghi, M., Mannani, R., Heidarnejad Maleki, A., Hamidi, A., Rostami, S., Safa, S. H., et al. (2023). Recent advances in non-small cell lung cancer targeted therapy. An update review. Cancer Cell International, 23(1), 162. https://doi.org/10.1186/s12935-023-02990-y
doi: 10.1186/s12935-023-02990-y
pubmed: 37568193
Howlader, N., Forjaz, G., Mooradian, M. J., Meza, R., Kong, C. Y., Cronin, K. A., et al. (2020). The effect of advances in lung-cancer treatment on population mortality. New England Journal of Medicine, 383(7), 640–649. https://doi.org/10.1056/NEJMoa1916623
doi: 10.1056/NEJMoa1916623
pubmed: 32786189
National Cancer Institute. (2023). Cancer stat facts: Lung and bronchus cancer. https://seer.cancer.gov/statfacts/html/lungb.html . Accessed 13 Jul 2023
Aberle, D. R., Adams, A. M., Berg, C. D., Black, W. C., Clapp, J. D., Fagerstrom, R. M., et al. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. New England Journal of Medicine, 365(5), 395–409. https://doi.org/10.1056/NEJMoa1102873
doi: 10.1056/NEJMoa1102873
pubmed: 21714641
Krist, A. H., Davidson, K. W., Mangione, C. M., Barry, M. J., Cabana, M., Caughey, A. B., et al. (2021). Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA, 325(10), 962–970. https://doi.org/10.1001/jama.2021.1117
doi: 10.1001/jama.2021.1117
pubmed: 33687470
Haddad, D. N., Sandler, K. L., Henderson, L. M., Rivera, M. P., & Aldrich, M. C. (2020). Disparities in lung cancer screening: A review. Annals of the American Thoracic Society, 17(4), 399–405. https://doi.org/10.1513/AnnalsATS.201907-556CME
doi: 10.1513/AnnalsATS.201907-556CME
pubmed: 32017612
pmcid: 7175982
Arrazola, R. A., Griffin, T., Lunsford, N. B., Kittner, D., Bammeke, P., Courtney-Long, E. A., et al. (2023). US cigarette smoking disparities by race and ethnicity - Keep going and going! Preventing Chronic Disease, 20, E45. https://doi.org/10.5888/pcd20.220375
doi: 10.5888/pcd20.220375
pubmed: 37262328
pmcid: 10240929
Murphy, S. E., Park, S. L., Balbo, S., Haiman, C. A., Hatsukami, D. K., Patel, Y., et al. (2018). Tobacco biomarkers and genetic/epigenetic analysis to investigate ethnic/racial differences in lung cancer risk among smokers. NPJ Precision Oncology, 2, 17. https://doi.org/10.1038/s41698-018-0057-y
doi: 10.1038/s41698-018-0057-y
pubmed: 30155522
pmcid: 6105591
Stram, D. O., Park, S. L., Haiman, C. A., Murphy, S. E., Patel, Y., Hecht, S. S., et al. (2019). Racial/ethnic differences in lung cancer incidence in the multiethnic cohort study: An update. Journal of the National Cancer Institute, 111(8), 811–819. https://doi.org/10.1093/jnci/djy206
doi: 10.1093/jnci/djy206
pubmed: 30698722
pmcid: 6695313
Giovino, G. A., Villanti, A. C., Mowery, P. D., Sevilimedu, V., Niaura, R. S., Vallone, D. M., et al. (2015). Differential trends in cigarette smoking in the USA: Is menthol slowing progress? Tobacco Control, 24(1), 28–37. https://doi.org/10.1136/tobaccocontrol-2013-051159
doi: 10.1136/tobaccocontrol-2013-051159
pubmed: 23997070
Arauz, R. F., Mayer, M., Reyes-Guzman, C., & Ryan, B. M. (2022). Racial disparities in cigarette smoking behaviors and differences stratified by metropolitan area of residence. International Journal of Public Health, 19(5). https://doi.org/10.3390/ijerph19052910
Furlow, B. (2023). US Government finally moves to ban menthol cigarettes. The Lancet Respiratory Medicine, 11(12), 1048–1049. https://doi.org/10.1016/s2213-2600(23)00413-7
doi: 10.1016/s2213-2600(23)00413-7
pubmed: 37924829
Baiu, I., Titan, A. L., Martin, L. W., Wolf, A., & Backhus, L. (2021). The role of gender in non-small cell lung cancer: A narrative review. Journal of Thoracic Disease, 13(6), 3816–3826. https://doi.org/10.21037/jtd-20-3128
doi: 10.21037/jtd-20-3128
pubmed: 34277072
pmcid: 8264700
Clément-Duchêne, C., Stock, S., Xu, X., Chang, E. T., Gomez, S. L., West, D. W., et al. (2016). Survival among never-smokers with lung cancer in the cancer care outcomes research and surveillance study. Annals of the American Thoracic Society, 13(1), 58–66. https://doi.org/10.1513/AnnalsATS.201504-241OC
doi: 10.1513/AnnalsATS.201504-241OC
pubmed: 26730864
pmcid: 5461981
Al Omari, O., Jani, C., Ahmed, A., Singh, H., Radwan, A., Bhatt, P., et al. (2023). Lung cancer mortality in the United States between 1999 and 2019: An observational analysis of disparities by sex and race. Annals of the American Thoracic Society, 20(4), 612–616. https://doi.org/10.1513/AnnalsATS.202206-510RL
doi: 10.1513/AnnalsATS.202206-510RL
pubmed: 36476451
pmcid: 10112410
Carrot-Zhang, J., Soca-Chafre, G., Patterson, N., Thorner, A. R., Nag, A., Watson, J., et al. (2021). Genetic ancestry contributes to somatic mutations in lung cancers from admixed Latin American populations. Cancer Discovery, 11(3), 591–598. https://doi.org/10.1158/2159-8290.Cd-20-1165
doi: 10.1158/2159-8290.Cd-20-1165
pubmed: 33268447
Midha, A., Dearden, S., & McCormack, R. (2015). EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII). American Journal of Cancer Research, 5(9), 2892–2911. www.ajcr.us
DeRouen, M. C., Canchola, A. J., Thompson, C. A., Jin, A., Nie, S., Wong, C., et al. (2022). Incidence of lung cancer among never-smoking Asian American, Native Hawaiian, and Pacific Islander Females. Journal of the National Cancer Institute, 114(1), 78–86. https://doi.org/10.1093/jnci/djab143
doi: 10.1093/jnci/djab143
pubmed: 34345919
Viñal, D., Martínez, D., Higuera, O., & de Castro, J. (2021). Genomic profiling in non-small-cell lung cancer in young patients. A systematic review. ESMO Open, 6(1), 100045. https://doi.org/10.1016/j.esmoop.2020.100045
doi: 10.1016/j.esmoop.2020.100045
pubmed: 33516149
pmcid: 7844571
Jemal, A., Miller, K. D., Ma, J., Siegel, R. L., Fedewa, S. A., Islami, F., et al. (2018). Higher lung cancer incidence in young women than young men in the United States. New England Journal of Medicine, 378(21), 1999–2009. https://doi.org/10.1056/NEJMoa1715907
doi: 10.1056/NEJMoa1715907
pubmed: 29791813
Centers for Disease Control and Prevention. (2022). United states cancer statistics: Data visualizations. https://gis.cdc.gov/Cancer/USCS/?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcancer%2Fdataviz%2Findex.htm#/NationalPrevalence/ . Accessed 28 Jul 2023
National Cancer Institute. (2023). Cancer stat facts: Cancer among adolescents and young adults (AYAs) (Ages 15–39): New Cases and Deaths 2023. https://seer.cancer.gov/statfacts/html/aya.html . Accessed 13 Jul 2023
Oliveira, I., Mota, P., & Almodovar, T. (2022). Lung cancer in young patients: Natural history, biology and prognosis. Pulmonology, 28(1), 80–81. https://doi.org/10.1016/j.pulmoe.2021.08.010
doi: 10.1016/j.pulmoe.2021.08.010
pubmed: 34625388
Arnold, B. N., Thomas, D. C., Rosen, J. E., Salazar, M. C., Blasberg, J. D., Boffa, D. J., et al. (2016). Lung cancer in the very young: Treatment and survival in the national cancer data base. Journal of Thoracic Oncology, 11(7), 1121–1131. https://doi.org/10.1016/j.jtho.2016.03.023
doi: 10.1016/j.jtho.2016.03.023
pubmed: 27103511
Cornelius, M. E., Loretan, C. G., Wang, T. W., Jamal, A., & Homa, D. M. (2022). Tobacco product use among adults - United States, 2020. Morbidity and Mortality Weekly Report, 71(11), 397–405. https://doi.org/10.15585/mmwr.mm7111a1
doi: 10.15585/mmwr.mm7111a1
pubmed: 35298455
pmcid: 8942309
Sahar, L., Douangchai Wills, V. L., Liu, K. K. A., Fedewa, S. A., Rosenthal, L., Kazerooni, E. A., et al. (2022). Geographic access to lung cancer screening among eligible adults living in rural and urban environments in the United States. Cancer, 128(8), 1584–1594. https://doi.org/10.1002/cncr.33996
doi: 10.1002/cncr.33996
pubmed: 35167123
Kish, J. K., Yu, M., Percy-Laurry, A., & Altekruse, S. F. (2014). Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in Surveillance, Epidemiology, and End Results (SEER) Registries. Journal of the National Cancer Institute Monographs, 2014(49), 236–243. https://doi.org/10.1093/jncimonographs/lgu020
doi: 10.1093/jncimonographs/lgu020
pubmed: 25417237
pmcid: 4841168
Morris, B. B., Hughes, R., Fields, E. C., Sabo, R. T., Weaver, K. E., & Fuemmeler, B. F. (2023). Sociodemographic and clinical factors associated with radiation treatment nonadherence and survival among rural and nonrural patients with cancer. International Journal of Radiation Oncology Biology Physics, 116(1), 28–38. https://doi.org/10.1016/j.ijrobp.2022.06.075
doi: 10.1016/j.ijrobp.2022.06.075
pubmed: 35777674
Sosa, E., D’Souza, G., Akhtar, A., Sur, M., Love, K., Duffels, J., et al. (2021). Racial and socioeconomic disparities in lung cancer screening in the United States: A systematic review. CA: A Cancer Journal for Clinicians, 71(4), 299–314. https://doi.org/10.3322/caac.21671
doi: 10.3322/caac.21671
pubmed: 34015860
Jones, G. S., & Baldwin, D. R. (2018). Recent advances in the management of lung cancer. Clinical Medicine (London, England), 18(Suppl 2), s41–s46. https://doi.org/10.7861/clinmedicine.18-2-s41
doi: 10.7861/clinmedicine.18-2-s41
pubmed: 29700092
de Koning, H. J., van der Aalst, C. M., de Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A., et al. (2020). Reduced lung-cancer mortality with volume CT screening in a randomized trial. New England Journal of Medicine, 382(6), 503–513. https://doi.org/10.1056/NEJMoa1911793
doi: 10.1056/NEJMoa1911793
pubmed: 31995683
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
Fedewa, S. A., Bandi, P., Smith, R. A., Silvestri, G. A., & Jemal, A. (2022). Lung cancer screening rates during the COVID-19 pandemic. Chest, 161(2), 586–589. https://doi.org/10.1016/j.chest.2021.07.030
doi: 10.1016/j.chest.2021.07.030
pubmed: 34298006
Niranjan, S. J., Opoku-Agyeman, W., Carroll, N. W., Dorsey, A., Tipre, M., Baskin, M. L., et al. (2021). Distribution and geographic accessibility of lung cancer screening centers in the United States. Annals of the American Thoracic Society, 18(9), 1577–1580. https://doi.org/10.1513/AnnalsATS.202010-1313RL
doi: 10.1513/AnnalsATS.202010-1313RL
pubmed: 33784236
pmcid: 8663474
Zgodic, A., Zahnd, W. E., Advani, S., & Eberth, J. M. (2022). Low-dose CT lung cancer screening uptake: A rural-urban comparison. The Journal of Rural Health, 38(1), 40–53. https://doi.org/10.1111/jrh.12568
doi: 10.1111/jrh.12568
pubmed: 33734492
Zarinshenas, R., Amini, A., Mambetsariev, I., Abuali, T., Fricke, J., Ladbury, C., et al. (2023). Assessment of barriers and challenges to screening, diagnosis, and biomarker testing in early-stage lung cancer. Cancers (Basel), 15(5). https://doi.org/10.3390/cancers15051595
US Census Bureau. (2020). 2020 census demographic data map viewer. https://www.census.gov/library/visualizations/2021/geo/demographicmapviewer.html . Accessed 20 July 2023
Narayan, A. K., Chowdhry, D. N., Fintelmann, F. J., Little, B. P., Shepard, J. O., & Flores, E. J. (2021). Racial and ethnic disparities in lung cancer screening eligibility. Radiology, 301(3), 712–720. https://doi.org/10.1148/radiol.2021204691
doi: 10.1148/radiol.2021204691
pubmed: 34546133
Harrison, S., Judd, J., Chin, S., & Ragin, C. (2022). Disparities in lung cancer treatment. Current Oncology Reports, 24(2), 241–248. https://doi.org/10.1007/s11912-022-01193-4
doi: 10.1007/s11912-022-01193-4
pubmed: 35080738
pmcid: 8965800
Japuntich, S. J., Krieger, N. H., Salvas, A. L., & Carey, M. P. (2018). Racial disparities in lung cancer screening: An exploratory investigation. Journal of the National Medical Association, 110(5), 424–427. https://doi.org/10.1016/j.jnma.2017.09.003
doi: 10.1016/j.jnma.2017.09.003
pubmed: 30129479
Aldrich, M. C., Mercaldo, S. F., Sandler, K. L., Blot, W. J., Grogan, E. L., & Blume, J. D. (2019). Evaluation of USPSTF lung cancer screening guidelines among African American adult smokers. JAMA Oncology, 5(9), 1318–1324. https://doi.org/10.1001/jamaoncol.2019.1402
doi: 10.1001/jamaoncol.2019.1402
pubmed: 31246249
pmcid: 6604090
Tanner, N. T., Gebregziabher, M., Hughes Halbert, C., Payne, E., Egede, L. E., & Silvestri, G. A. (2015). Racial differences in outcomes within the National Lung Screening Trial. Implications for widespread implementation. American Journal of Respiratory and Critical Care Medicine, 192(2), 200–208. https://doi.org/10.1164/rccm.201502-0259OC
doi: 10.1164/rccm.201502-0259OC
pubmed: 25928649
Kligerman, S., & White, C. (2011). Epidemiology of lung cancer in women: Risk factors, survival, and screening. AJR. American Journal of Roentgenology, 196(2), 287–295. https://doi.org/10.2214/ajr.10.5412
doi: 10.2214/ajr.10.5412
pubmed: 21257878
Duma, N. (2020). Lung-cancer researchers and clinicians must pay more attention to women. Nature, 587(7834), S13. https://doi.org/10.1038/d41586-020-03151-1
doi: 10.1038/d41586-020-03151-1
pubmed: 33208973
Ragavan, M., & Patel, M. I. (2022). The evolving landscape of sex-based differences in lung cancer: A distinct disease in women. European Respiratory Review, 31(163). https://doi.org/10.1183/16000617.0100-2021
Reese, T. J., Schlechter, C. R., Potter, L. N., Kawamoto, K., Del Fiol, G., Lam, C. Y., et al. (2021). Evaluation of revised US Preventive Services Task Force lung cancer screening guideline among women and racial/ethnic minority populations. JAMA Network Open, 4(1), e2033769. https://doi.org/10.1001/jamanetworkopen.2020.33769
doi: 10.1001/jamanetworkopen.2020.33769
pubmed: 33433600
pmcid: 7804914
Rivera, M. P., Katki, H. A., Tanner, N. T., Triplette, M., Sakoda, L. C., Wiener, R. S., et al. (2020). Addressing disparities in lung cancer screening eligibility and healthcare access. An official American Thoracic Society statement. American Journal of Respiratory and Critical Care Medicine, 202(7), e95–e112. https://doi.org/10.1164/rccm.202008-3053ST
doi: 10.1164/rccm.202008-3053ST
pubmed: 33000953
pmcid: 7528802
Steiling, K., Kathuria, H., Echieh, C. P., Ost, D. E., Rivera, M. P., Begnaud, A., et al. (2023). Research priorities for interventions to address health disparities in lung nodule management: An official American Thoracic Society research statement. American Journal of Respiratory and Critical Care Medicine, 207(6), e31–e46. https://doi.org/10.1164/rccm.202212-2216ST
doi: 10.1164/rccm.202212-2216ST
pubmed: 36920066
pmcid: 10037482
Borondy Kitts, A. K. (2019). The patient perspective on lung cancer screening and health disparities. Journal of the American College of Radiology, 16(4 Pt B), 601–606. https://doi.org/10.1016/j.jacr.2018.12.028
doi: 10.1016/j.jacr.2018.12.028
pubmed: 30947894
Deppen, S. A., Grogan, E. L., Aldrich, M. C., & Massion, P. P. (2014). Lung cancer screening and smoking cessation: A teachable moment? Journal of the National Cancer Institute, 106(6), dju122. https://doi.org/10.1093/jnci/dju122
doi: 10.1093/jnci/dju122
pubmed: 24872542
pmcid: 5073840
Sands, J., Tammemägi, M. C., Couraud, S., Baldwin, D. R., Borondy-Kitts, A., Yankelevitz, D., et al. (2021). Lung screening benefits and challenges: A review of the data and outline for implementation. Journal of Thoracic Oncology, 16(1), 37–53. https://doi.org/10.1016/j.jtho.2020.10.127
doi: 10.1016/j.jtho.2020.10.127
pubmed: 33188913
Wiener, R. S., & Gould, M. K. (2023). Selecting candidates for lung cancer screening: Implications for effectiveness, efficiency, equity, and implementation. Annals of Internal Medicine, 176(3), 413–414. https://doi.org/10.7326/m23-0230
doi: 10.7326/m23-0230
pubmed: 36745888
Mazzone, P. J., Silvestri, G. A., Souter, L. H., Caverly, T. J., Kanne, J. P., Katki, H. A., et al. (2021). Screening for lung cancer: CHEST guideline and expert panel report. Chest, 160(5), e427–e494. https://doi.org/10.1016/j.chest.2021.06.063
doi: 10.1016/j.chest.2021.06.063
pubmed: 34270968
pmcid: 8727886
van Os, S., Syversen, A., Whitaker, K. L., Quaife, S. L., Janes, S. M., Jallow, M., et al. (2022). Lung cancer symptom appraisal, help-seeking and diagnosis - Rapid systematic review of differences between patients with and without a smoking history. Psycho-Oncology, 31(4), 562–576. https://doi.org/10.1002/pon.5846
doi: 10.1002/pon.5846
pubmed: 34766413
Healthcare Safety Investigation Branch. (2022). Missed detection of lung cancer on chest X-rays of patients being seen in primary care. https://www.hssib.org.uk/patient-safety-investigations/missed-detection-of-lung-cancer-on-chest-x-rays-of-patients-being-seen-in-primary-care/investigation-report/ . Accessed 13 Jul 2023
Singh, N., Aggarwal, A. N., Gupta, D., Behera, D., & Jindal, S. K. (2012). Quantified smoking status and non-small cell lung cancer stage at presentation: Analysis of a North Indian cohort and a systematic review of literature. Journal of Thoracic Disease, 4(5), 474–484. https://doi.org/10.3978/j.issn.2072-1439.2012.05.11
doi: 10.3978/j.issn.2072-1439.2012.05.11
pubmed: 23050111
pmcid: 3461078
Hung, H. Y., Tseng, Y. H., Chao, H. S., Chiu, C. H., Hsu, W. H., Hsu, H. S., et al. (2020). Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer. PLoS One, 15(10), e0236503. https://doi.org/10.1371/journal.pone.0236503
doi: 10.1371/journal.pone.0236503
pubmed: 33031375
pmcid: 7544080
Varma, T., Mello, M., Ross, J. S., Gross, C., & Miller, J. (2023). Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: Retrospective cross sectional study. BMJ Medicine, 2(1), e000395. https://doi.org/10.1136/bmjmed-2022-000395
doi: 10.1136/bmjmed-2022-000395
pubmed: 36936269
pmcid: 9951369
Bodicoat, D. H., Routen, A. C., Willis, A., Ekezie, W., Gillies, C., Lawson, C., et al. (2021). Promoting inclusion in clinical trials-A rapid review of the literature and recommendations for action. Trials, 22(1), 880. https://doi.org/10.1186/s13063-021-05849-7
doi: 10.1186/s13063-021-05849-7
pubmed: 34863265
pmcid: 8643184
Yusuf, R. A., Rogith, D., Hovick, S. R., Peterson, S. K., Burton-Chase, A. M., Fellman, B. M., et al. (2015). Attitudes toward molecular testing for personalized cancer therapy. Cancer, 121(2), 243–250. https://doi.org/10.1002/cncr.28966
doi: 10.1002/cncr.28966
pubmed: 25209923
Hofmarcher, T., Malmberg, C., & Lindgren, P. (2023). A global analysis of the value of precision medicine in oncology - The case of non-small cell lung cancer. Frontiers in Medicine (Lausanne), 10, 1119506. https://doi.org/10.3389/fmed.2023.1119506
doi: 10.3389/fmed.2023.1119506
Musika, W., Kamsa-Ard, S., Jirapornkul, C., Santong, C., & Phunmanee, A. (2021). Lung cancer survival with current therapies and new targeted treatments: A comprehensive update from the Srinagarind Hospital-Based Cancer Registry from (2013 to 2017). Asian Pacific Journal of Cancer Prevention, 22(8), 2501–2507. https://doi.org/10.31557/apjcp.2021.22.8.2501
doi: 10.31557/apjcp.2021.22.8.2501
pubmed: 34452564
pmcid: 8629471
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Jr., Wu, Y. L., et al. (2017). Lung cancer: Current therapies and new targeted treatments. Lancet, 389(10066), 299–311. https://doi.org/10.1016/s0140-6736(16)30958-8
doi: 10.1016/s0140-6736(16)30958-8
pubmed: 27574741
Martin, C. (2021). Perceptions of biomarker testing for underserved patients with lung cancer: A mixed-methods survey of U.S.-based oncology clinicians. https://www.iaslc.org/iaslc-news/press-release/perceptions-biomarker-testing-underserved-patients-lung-cancer-mixed . Accessed 1 Nov 2023
Vanderpoel, J., Stevens, A. L., Emond, B., Lafeuille, M. H., Hilts, A., Lefebvre, P., et al. (2022). Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer. Journal of Medical Economics, 25(1), 457–468. https://doi.org/10.1080/13696998.2022.2053403
doi: 10.1080/13696998.2022.2053403
pubmed: 35289703
Sadik, H., Pritchard, D., Keeling, D. M., Policht, F., Riccelli, P., Stone, G., et al. (2022). Impact of clinical practice gaps on the implementation of personalized medicine in advanced non–small-cell lung cancer. JCO Precision Oncology, 6, e2200246. https://doi.org/10.1200/po.22.00246
doi: 10.1200/po.22.00246
pubmed: 36315914
pmcid: 9666118
Kalemkerian, G. P., Narula, N., Kennedy, E. B., Biermann, W. A., Donington, J., Leighl, N. B., et al. (2018). Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. Journal of Clinical Oncology, 36(9), 911–919. https://doi.org/10.1200/jco.2017.76.7293
doi: 10.1200/jco.2017.76.7293
pubmed: 29401004
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
Villalobos, P., & Wistuba, I. I. (2017). Lung cancer biomarkers. Hematology/oncology Clinics of North America, 31(1), 13–29. https://doi.org/10.1016/j.hoc.2016.08.006
doi: 10.1016/j.hoc.2016.08.006
pubmed: 27912828
pmcid: 5137804
Luchini, C., Bibeau, F., Ligtenberg, M. J. L., Singh, N., Nottegar, A., Bosse, T., et al. (2019). ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach. Annals of Oncology, 30(8), 1232–1243. https://doi.org/10.1093/annonc/mdz116
doi: 10.1093/annonc/mdz116
pubmed: 31056702
Holmes, M., Mahar, A., Lum, T., Boyer, M., Kao, S., & Cooper, W. (2019). Prevalence of PD-L1 expression rates in different NSCLC specimens. Journal of Thoracic Oncology, 14(10_suppl), S506. Poster P1.09-26. https://doi.org/10.1016/j.jtho.2019.08.1055
Kerr, K. M., Bibeau, F., Thunnissen, E., Botling, J., Ryška, A., Wolf, J., et al. (2021). The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer, 154, 161–175. https://doi.org/10.1016/j.lungcan.2021.02.026
doi: 10.1016/j.lungcan.2021.02.026
pubmed: 33690091
US Food and Drug Administration. (2021). FDA approves pembrolizumab for adults and children with TMB-H solid tumors. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors . Accessed 13 Jun 2023
Farago, A. F., Taylor, M. S., Doebele, R. C., Zhu, V. W., Kummar, S., Spira, A. I. (2018). Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion. JCO Precision Oncology, 2018 https://doi.org/10.1200/po.18.00037
Rolfo, C., Mack, P., Scagliotti, G. V., Aggarwal, C., Arcila, M. E., Barlesi, F., et al. (2021). Liquid biopsy for advanced NSCLC: A consensus statement from the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology, 16(10), 1647–1662. https://doi.org/10.1016/j.jtho.2021.06.017
doi: 10.1016/j.jtho.2021.06.017
pubmed: 34246791
US Food and Drug Administration. (2023). List of cleared or approved companion diagnostic devices (in vitro and imaging tools). https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools . Accessed 18 Jul 2023
Odegaard, J. I., Vincent, J. J., Mortimer, S., Vowles, J. V., Ulrich, B. C., Banks, K. C., et al. (2018). Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. Clinical Cancer Research, 24(15), 3539–3549. https://doi.org/10.1158/1078-0432.Ccr-17-3831
doi: 10.1158/1078-0432.Ccr-17-3831
pubmed: 29691297
Leighl, N. B., Page, R. D., Raymond, V. M., Daniel, D. B., Divers, S. G., Reckamp, K. L., et al. (2019). Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clinical Cancer Research, 25(15), 4691–4700. https://doi.org/10.1158/1078-0432.Ccr-19-0624
doi: 10.1158/1078-0432.Ccr-19-0624
pubmed: 30988079
Mack, P. C., Banks, K. C., Espenschied, C. R., Burich, R. A., Zill, O. A., Lee, C. E., et al. (2020). Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases. Cancer, 126(14), 3219–3228. https://doi.org/10.1002/cncr.32876
doi: 10.1002/cncr.32876
pubmed: 32365229
Levy, B. P., Chioda, M. D., Herndon, D., Longshore, J. W., Mohamed, M., Ou, S. H., et al. (2015). Molecular testing for treatment of metastatic non-small cell lung cancer: How to implement evidence-based recommendations. The Oncologist, 20(10), 1175–1181. https://doi.org/10.1634/theoncologist.2015-0114
doi: 10.1634/theoncologist.2015-0114
pubmed: 26330460
pmcid: 4591939
Anand, K., Phung, T. L., Bernicker, E. H., Cagle, P. T., Olsen, R. J., & Thomas, J. S. (2020). Clinical utility of reflex ordered testing for molecular biomarkers in lung adenocarcinoma. Clinical Lung Cancer, 21(5), 437–442. https://doi.org/10.1016/j.cllc.2020.05.007
doi: 10.1016/j.cllc.2020.05.007
pubmed: 32600793
Slavik, T., Asselah, F., Fakhruddin, N., El Khodary, A., Torjman, F., Anis, E., et al. (2014). Diagnosis and predictive molecular analysis of non-small-cell lung cancer in the Africa-Middle East region: Challenges and strategies for improvement. Clinical Lung Cancer, 15(6), 398–404. https://doi.org/10.1016/j.cllc.2014.06.005
doi: 10.1016/j.cllc.2014.06.005
pubmed: 25043210
Boehmer, L., Roy, U., Schrag, J., Martin, N., Salinas, G., Coleman, B., et al. (2021). OA10.01 Perceptions of biomarker testing for underserved patients with lung cancer: A mixed-methods survey of US-based oncology clinicians. Journal of Thoracic Oncology, 16(10_suppl), S863–S864. https://doi.org/10.1016/j.jtho.2021.08.064
doi: 10.1016/j.jtho.2021.08.064
Zer, A., Cutz, J. C., Sekhon, H., Hwang, D. M., Sit, C., Maganti, M., et al. (2018). Translation of knowledge to practice-improving awareness in NSCLC molecular testing. Journal of Thoracic Oncology, 13(7), 1004–1011. https://doi.org/10.1016/j.jtho.2018.03.005
doi: 10.1016/j.jtho.2018.03.005
pubmed: 29535011
Hsiao, S. J., Sireci, A. N., Pendrick, D., Freeman, C., Fernandes, H., Schwartz, G. K., et al. (2020). Clinical utilization, utility, and reimbursement for expanded genomic panel testing in adult oncology. JCO Precision Oncology, 4, 1038–1048. https://doi.org/10.1200/po.20.00048
doi: 10.1200/po.20.00048
pubmed: 35050771
Desai, K., Hooker, G., Gilbert, K., Cropper, C., Metcalf, R., & Kachroo, S. (2021). Real-world trends in costs of next generation sequencing (NGS) testing in US setting. Journal of Clinical Oncology, 39(15_suppl), e18824–e18824. https://doi.org/10.1200/JCO.2021.39.15_suppl.e18824
doi: 10.1200/JCO.2021.39.15_suppl.e18824
Ray, T. (2017). CMS 14-day rule revisions ease precision medicine access for patients, stakeholders say. https://www.precisionmedicineonline.com/reimbursement/cms-14-day-rule-revisions-ease-precision-medicine-access-patients-stakeholders-say . Accessed 3 Jun 2023
Centers for Medicare & Medicaid Services. (2018). Next Generation Sequencing (NGS) for Medicare beneficiaries with advanced cancer. https://www.cms.gov/medicare-coverage-database/view/ncacal-tracking-sheet.aspx?NCAId=296 . Accessed 13 Jul 2023